ReviewBreast cancer (Dove Medical Press)2016
Pharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancer.
Review in Breast cancer (Dove Medical Press), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 25 citations in OpenAlex.
- Catalase: The golden key to regulate oxidative stress in breast cancer.World journal of clinical oncology · 2025Review
- Preoperative platelet distribution width predicts bone metastasis in patients with breast cancer.BMC cancer · 2024Article
- IBSP Promotes Breast Cancer Bone Metastasis and Proliferation via BMP-SMAD Signaling Pathway.Cancer reports (Hoboken, N.J.) · 2024Article
- Aromatase Inhibitor Musculoskeletal Syndrome and Bone Loss: a Review of the Current Literature.Current oncology reports · 2023Review
- Lower subcutaneous fat index predicts bone metastasis in breast cancer.Cancer biomarkers : section A of Disease markers · 2023Article
- The role played by ailanthone in inhibiting bone metastasis of breast cancer by regulating tumor-bone microenvironment through the RANKL-dependent pathway.Frontiers in pharmacology · 2022Article
- Predicting Response to Radiotherapy in Breast Cancer-Induced Bone Pain: Relationship Between Pain and Serum Cytokine Expression Levels After Radiotherapy.Journal of pain research · 2022Article
- Expression levels and clinical values of miR-92b-3p in breast cancer.World journal of surgical oncology · 2021Article
- Aromatase Inhibitor-Associated Musculoskeletal Syndrome: Understanding Mechanisms and Management.Frontiers in endocrinology · 2021Review
- Application of Biomarkers for the Prediction and Diagnosis of Bone Metastasis in Breast Cancer.Journal of breast cancer · 2020Review
- Expression of miR-129-5p and miR-433 in the serum of breast cancer patients and their relationship with clinicopathological features.Oncology letters · 2020Article
- Activating human epidermal growth factor receptor 2 (HER2) gene mutation in bone metastases from breast cancer.Virchows Archiv : an international journal of pathology · 2018Article
- Estrogen receptor (ESR1) mutation in bone metastases from breast cancer.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2018Article
- Rutin Isolated fromOxidative medicine and cellular longevity · 2018Article
- Bone morphogenetic proteins, breast cancer, and bone metastases: striking the right balance.Endocrine-related cancer · 2017Review
- Phenolics Isolated from Aframomum meleguta Enhance Proliferation and Ossification Markers in Bone Cells.Molecules (Basel, Switzerland) · 2017Article
- Are another 5 years of adjuvant aromatase inhibitor therapy needed?Breast cancer (Dove Medical Press) · 2016Article
- Ghrelin Induces the Production of Hypothalamic NPY Through the AMPK-mTOR Pathway to Alleviate Cancer-induced Bone Pain.In vivo (Athens, Greece)Article
- Increased Expression of Follistatin in Breast Cancer Reduces Invasiveness and Clinically Correlates with Better Survival.Cancer genomics & proteomicsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is a high risk for bone loss and skeletal-related events, including bone metastases, in postmenopausal women with hormone receptor-positive breast cancer. Both the disease itself and its therapeutic treatments can negatively impact bone, resulting in decreases in bone mineral density and increases in bone loss. These negative effects on the bone can significantly impact morbidity and mortality. Effective management and minimization of bone-related complications in postmenopausal women with hormone receptor-positive breast cancer remain essential. This review discusses the current understanding of molecular and biological mechanisms involved in bone turnover and metastases, increased risk for bone-related complications from breast cancer and breast cancer therapy, and current and emerging treatment strategies for managing bone metastases and bone turnover in postmenopausal women with hormone receptor-positive breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.